Search results
Results from the WOW.Com Content Network
Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics [3] for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. [4]
Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY), a biotech company developing a new class of medications based on RNAi technology, have soared 250% since the start of 2013. Why are investors so ...
(Reuters) -Alnylam Pharmaceuticals said on Friday it plans to appeal a ruling by the U.S. District Court for the District of Delaware on two patents asserted against Moderna for the latter's COVID ...
Alnylam has also formed Alnylam Biotherapeutics, a division of the company focused on the development of RNAi technologies for applications in biologics manufacturing, including recombinant ...
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, announced today that it has presented new pre-clinical data with an RNAi ...
PARSIPPANY, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- The Medicines Company (NAS: MDCO) and Alnylam Pharmaceuticals, Inc. (NAS: ALNY) , a leading RNAi therapeutics company, announced today that ...
Regulus was established in September 2007 by Alnylam Pharmaceuticals and Isis Pharmaceuticals. [1] microRNA explained
Alnylam has closed on its previously announced acquisition of Merck's RNAi business, Sirna Therapeutics. That deal could prove one of the best buys in RNAi since Arrowhead walked away with Roche's ...